10x Genomics (TXG) Net Income towards Common Stockholders (2018 - 2026)

10x Genomics has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$13.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 60.8% year-over-year to -$13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.7 million (up 85.57% YoY) and the FY2025 annual result came in at -$43.5 million, up 76.16% from the prior year.
• Net Income towards Common Stockholders climbed to -$13.5 million in Q1 2026 per TXG's latest filing, from -$16.3 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $34.5 million in Q2 2025 and troughed at -$93.0 million in Q3 2023.
• A 5-year average of -$38.9 million and a median of -$41.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders sank 483.22% in 2022, then jumped 191.14% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$17.2 million in 2022, then tumbled by 184.36% to -$49.0 million in 2023, then fell by 0.16% to -$49.0 million in 2024, then jumped by 66.85% to -$16.3 million in 2025, then advanced by 17.12% to -$13.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$13.5 million, -$16.3 million, and -$27.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.